Navigation Links
Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
Date:4/16/2008

PRINCETON, N.J., April 16 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today data from a Phase 1/2 trial that suggest a potential association between higher doses of MDX-060, an investigational anti-CD30 antibody, and improvement in disease control and prolonged progression-free survival in patients with relapsed or refractory CD30- positive lymphomas. Results from the Phase 1/2 trial were presented at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego (Abstract #5525).

"We continue to assess the potential for anti-CD30 antibody therapies in the marketplace and are pleased with the findings of this exploratory study," said Howard H. Pien, President and CEO of Medarex. "We look forward to analyzing these results alongside the Phase 2 proof-of-concept chemotherapy combination data that is expected later in the year."

In the completed dose-escalation Phase 1/2 trial, 72 patients with relapsed or refractory CD30-positive lymphoma received weekly doses of MDX-060 (0.1, 1, 4, 10 or 15 mg/kg) for four weeks. Of the 33 patients treated at the two highest doses of MDX-060, disease control was observed in 51 percent of patients (3 complete responses, 14 stable disease), with median progression- free survival of 3.7 months and 39 percent of patients with no evidence of disease progression four months post-treatment. Of the 39 patients treated at the three lowest doses of MDX-060, disease control was observed in 33 percent of patients (1 complete response, 2 partial responses, 10 stable disease), with median progression-free survival of less than 2 months and 18 percent of patients with no evidence of disease progression four months post-treatment. MDX
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Cranford, NJ (PRWEB) August 27, 2014 ... and services – has once again shown superiority when ... trial sponsor by completing the ePRO portion of their ... results. The Japan-based pharma chose WriteResult’s digital writing ... IBS trials – the first to complete drew data ...
(Date:8/26/2014)... San Diego, CA, and Bellingham, WA (PRWEB) August ... nanoscience and optical engineering, visions for next-generation wearable ... Light 2015 among numerous highlights at this year’s ... in the San Diego, California, Convention Center. More ... suppliers last week attended conferences, courses, an exhibition, ...
(Date:8/26/2014)... to the growing case for graphene being bumped ... in the high-tech world by the two-dimensional semiconductors ... researchers led by a scientist with the U.S. ... (Berkeley Lab) has reported the first experimental observation ... The recorded charge transfer time clocked in at ...
(Date:8/26/2014)... ANN ARBOR, Mich. , Aug. 26, 2014 ... pioneering the development of breakthrough oral medicines to ... science of immune modulation, today announced the appointment ... of the company,s scientific advisory board.  Dr. Singh ... and insight to advance Lycera,s multiple ongoing research ...
Breaking Biology Technology:A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4Competition for graphene 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 3
... top line data from a Phase 2 clinical trial ... of Influenza-Like Illness (ILI) caused by all types and ... strains. In a double-blind, placebo-controlled, Phase 2 trial of ... DAS181 resulted in a significant reduction in patients, influenza ...
... (July 1, 2011) After Fukushima, it is now imperative ... from cradle to grave. If nuclear waste management is not ... will reject nuclear power as an energy choice, according to ... Atomic Scientists , published by SAGE. According to Allison ...
... just fifteen minutes to analyze a sample suspected of ... The technology amplifies any anthrax DNA present in the ... microscopic cells of the deadly bacteria Bacillus anthracis. ... lethal microbe that might be used intentionally to infect ...
Cached Biology Technology:NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 2NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 3NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 4Nuclear waste requires cradle-to-grave strategy 2Nuclear waste requires cradle-to-grave strategy 3Nano detector for deadly anthrax 2
(Date:8/25/2014)... diagnostic device invented at New Zealand,s University of ... field tool for rapidly detecting suspected viruses or ... of infection. , The breakthrough device, dubbed Freedom4, ... Biology main meeting. It takes advantage of a ... sequences in real-time, without the need for further ...
(Date:8/25/2014)... built like a nano-Christmas tree. Called a glycoconjugate, it,s ... those ornaments that get all the glory. That,s because, ... holds the sugars in place as they do the ... a chemist at Michigan Technological University has discovered that ... than a simple prop. , "We had always thought ...
(Date:8/25/2014)... A parasitic fungus that reproduces by manipulating the ... chemicals when encountering the brain of its natural ... species, a new study shows., The findings, which ... provide new insights into the molecular mechanisms underlying ... known for their ability to secrete chemicals that ...
Breaking Biology News(10 mins):Revolutionary handheld DNA diagnostic unit allows lab-quality analysis in the field 2Zombie ant fungi 'know' brains of their hosts 2Zombie ant fungi 'know' brains of their hosts 3
... Island of New Zealand is marked at approximately 38 S ... line". This region forms the southern distributional limit of many ... number of endemic plants are found there. Ecologists have recently ... the "kauri line". Wetlands serve vital ecological functions by ...
... and from Berkeley have used metal complexes to modify ... Chemical Society , they report for the first time ... "With this work, we have laid the molecular foundation ... Stoll from the Faculty of Chemistry and Biochemistry at ...
... MAResearchers from Brigham and Women,s Hospital (BWH) have made a ... The team, led by Thomas S. Kupper, MD, chair of ... that high expression of a cell-signaling molecule, known as interleukin-9, ... findings will be published online in the July 8, 2012 ...
Cached Biology News:A new species of wirerush from the wetlands in northern New Zealand 2A new avenue to better medicines: Metal-peptide complexes 2Researchers discover molecule in immune system that could help treat dangerous skin cancer 2
Applications: Immunohistochemistry, ISH, FISH, CISH....
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: